Last reviewed · How we verify
IP-001
At a glance
| Generic name | IP-001 |
|---|---|
| Sponsor | M.R. Meijerink |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases (PHASE2, PHASE3)
- Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. (PHASE1, PHASE2)
- Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone (PHASE2)
- Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM (PHASE1, PHASE2)
- Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IP-001 CI brief — competitive landscape report
- IP-001 updates RSS · CI watch RSS
- M.R. Meijerink portfolio CI